River blindness drug trial aims to find right dose for kids

NCT ID NCT03962062

Completed Disease control Sponsor: Medicines Development for Global Health Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a single dose of moxidectin in 36 children aged 4 to 17 who have or are at risk of onchocerciasis (river blindness). The goal was to find a dose for children 4-11 years that works like the standard 8 mg dose used in older kids and adults. Researchers measured drug levels in the blood and checked for side effects to ensure safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: moxidectin (a tablet taken by mouth)
What this could lead to: If successful, this could help determine a safe and effective dose of moxidectin for children aged 4-11 with onchocerciasis, potentially improving treatment access for younger patients.
What could go wrong: This is a small, early-phase study with only 36 participants, so results may not apply broadly. The trial focuses on drug levels and safety, not on curing the disease, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ONCHOCERCIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

onchocerciasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ONCHOCERCIASIS

Contacts and locations

Locations

University of Health and Allied Services School of Public Health

Hohoe, Volta Region, Ghana

More trials for these conditions

Other studies related to the condition(s) this trial covers.